Renal Cancer Drugs Market by Type (Clear Cell, Papillary, Chromophobe, Oncocytic, Collecting Duct), Brand (Sutent, Nexavar, Afinitor, Votrient, Inlyta, Avastin, Torisel, Proleukin) - Analysis and Global Forecast to 2019
Renal cancer commonly known as kidney cancer originates in the lining of the proximal convoluted tubule of the kidney. The renal cancer is caused by Von Hippel-Lindau (VHL) syndrome, obesity, smoking, high blood pressure, long-term dialysis, occupational exposure (for example asbestos workers). The symptoms of renal cancer include a lump or mass in the abdomen or side, blood in the urine, weight loss, fever, and lethargy. Several drugs for the treatment of renal cancer are currently available in the market. The global renal cancer drug market is likely to show significant growth during the forecast period. This is attributed to the rising incidences of renal cancer, increasing geriatric population, and approval of novel molecules to develop drugs. However, high prices of branded drugs to treat cancer and rising preference for generic drugs are expected to restrain the market for renal cancer drugs market. Categories of Renal Cancer Drugs The renal cancer drugs market i...